BRPI0412832A - uso terapêutico das yessotoxinas como inibidores do crescimento de células tumorais humanas - Google Patents
uso terapêutico das yessotoxinas como inibidores do crescimento de células tumorais humanasInfo
- Publication number
- BRPI0412832A BRPI0412832A BRPI0412832-0A BRPI0412832A BRPI0412832A BR PI0412832 A BRPI0412832 A BR PI0412832A BR PI0412832 A BRPI0412832 A BR PI0412832A BR PI0412832 A BRPI0412832 A BR PI0412832A
- Authority
- BR
- Brazil
- Prior art keywords
- cell growth
- yessotoxins
- inhibitors
- therapeutic use
- tumor cell
- Prior art date
Links
- 239000002463 yessotoxin Substances 0.000 title abstract 7
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 230000004565 tumor cell growth Effects 0.000 title abstract 3
- HCYDZFJGUKMTQB-AVHIVUAZSA-N yessotoxin Chemical compound C[C@H]([C@H]1O[C@H]2[C@@H](O)[C@@]3(C)O[C@H]4CC(=C)[C@H](O[C@@H]4C[C@@H]3O[C@@H]2C[C@@H]1O[C@@H]1C2)[C@](C)(O)\C=C\C(=C)CC=C)CC[C@]1(C)O[C@@]1(C)[C@H]2O[C@@H]2C[C@@H]3O[C@@H]4C[C@@H]5O[C@](C)(CCOS(O)(=O)=O)[C@@H](OS(O)(=O)=O)C[C@H]5O[C@H]4C[C@H]3O[C@H]2CC1 HCYDZFJGUKMTQB-AVHIVUAZSA-N 0.000 abstract 4
- QFTUOYVQWREZMQ-UHFFFAOYSA-N yessotoxin Natural products CC1CC2(C)OC3(C)CCC4OC5CC6OC7CC(OS(=O)(=O)O)C(C)(CCOS(=O)(=O)O)OC7CC6OC5CC4OC3CC2OC8CC9(C)OC%10CC%11OC(C(=C)CC%11OC%10(C)C(O)C9OC18)C(C)(O)C=CC(=C)CC=C QFTUOYVQWREZMQ-UHFFFAOYSA-N 0.000 abstract 4
- 230000004913 activation Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000001086 cytosolic effect Effects 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000005170 neoplastic cell Anatomy 0.000 abstract 1
- 230000008569 process Effects 0.000 abstract 1
- 230000009467 reduction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"USO TERAPêUTICO DAS YESSOTOXINAS COMO INIBIDORES DO CRESCIMENTO DE CéLULAS TUMORAIS HUMANAS". O Uso terapêutico das yessotoxinas como inibidores do crescimento de células tumorais humanas. O mecanismo de ação da yessotoxina (YTX) e de análogos está relacionado à ativação das fosfodiesterases celulares e, como conseqüência, à diminuição dos níveis citossólicos de AMPc. O resultado desta ativação, depois da administração de YTX, é uma inibição do crescimento de células de hepatocarcinoma humano. Este efeito citotóxico da YTX sobre células neoplásicas pode ser utilizado como estratégia para o desenvolvimento de fármacos úteis no tratamento de processos tumorais.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200301773A ES2235611B2 (es) | 2003-07-25 | 2003-07-25 | Metodo cuantitativo para la deteccion de yesotoxinas en productos pesqueros basado en la activacion que producen en las fosfodiesterasas. |
| PCT/ES2004/000343 WO2005012543A2 (es) | 2003-07-25 | 2004-07-21 | Método cuantitativo para la detección de yesotoxinas en productos pesqueros basado en la activación que la toxina produce en las fosfodiesterasas celulares y utilidad terapéutica de esta activación. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0412832A true BRPI0412832A (pt) | 2006-11-21 |
Family
ID=34112518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0412832-0A BRPI0412832A (pt) | 2003-07-25 | 2004-07-21 | uso terapêutico das yessotoxinas como inibidores do crescimento de células tumorais humanas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110065138A1 (pt) |
| EP (3) | EP1875906B1 (pt) |
| JP (2) | JP2006528483A (pt) |
| CN (1) | CN1852988A (pt) |
| AT (3) | ATE393833T1 (pt) |
| AU (3) | AU2004260895A1 (pt) |
| BR (1) | BRPI0412832A (pt) |
| CA (1) | CA2533600A1 (pt) |
| DE (1) | DE602004013446D1 (pt) |
| ES (4) | ES2235611B2 (pt) |
| RU (1) | RU2389488C2 (pt) |
| WO (1) | WO2005012543A2 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101382531B (zh) * | 2008-10-08 | 2011-12-28 | 天津商业大学 | 利用电子鼻检测虾新鲜度的方法 |
| ES2393696B2 (es) * | 2012-09-07 | 2013-06-04 | Universidade De Santiago De Compostela | Uso de la Yessotoxina y sus derivados para el tratamiento de gliomas |
| CN105198900A (zh) * | 2015-09-22 | 2015-12-30 | 国家海洋环境检测中心 | 虾夷扇贝毒素ytx纯品的提取、制备方法 |
| US10890573B2 (en) | 2017-12-19 | 2021-01-12 | International Business Machines Corporation | Facile methods to detect toxin in seafood |
| RU2716233C1 (ru) * | 2018-11-13 | 2020-03-10 | Федеральное государственное бюджетное учреждение науки "Федеральный исследовательский центр питания, биотехнологии и безопасности пищи" | Способ количественного определения йессотоксинов в моллюсках |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5672509A (en) * | 1993-08-25 | 1997-09-30 | Pfizer Inc. | hPDE IV-C: a human phosphodiesterase IV isozyme |
| US5858694A (en) * | 1997-05-30 | 1999-01-12 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of cancerous lesions |
| WO1999035283A1 (en) * | 1997-12-15 | 1999-07-15 | Beth Israel Deaconess Medical Center | Methods and reagents for modulating cell motility |
| RU2136278C1 (ru) * | 1998-04-07 | 1999-09-10 | Государственный научный центр вирусологии и биотехнологии "Вектор" | Противоопухолевое средство |
| WO2001072297A1 (en) * | 2000-03-27 | 2001-10-04 | The Scripps Research Institute | Methods for inhibiting angiogenesis and tumor growth |
| IT1318605B1 (it) | 2000-06-30 | 2003-08-27 | Uni Degli Studi Di Modena E Re | Procedimoento per il dosaggio di tossine dsp del gruppo delledinophysitossine e delle yessottossine. |
| US6977155B2 (en) * | 2000-08-10 | 2005-12-20 | Corning Incorporated | Arrays of biological membranes and methods and use thereof |
| AR033680A1 (es) * | 2000-08-30 | 2004-01-07 | Schering Corp | Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales |
| EP1251181A1 (en) * | 2001-04-20 | 2002-10-23 | Warner-Lambert Company | Non-recombinant cell lines capable of expressing predominantly cyclic nucleotide phosphodiesterase 4 (PDE4) subtype B and their use for the screening of PDE4 subtype-specific modulators |
-
2003
- 2003-07-25 ES ES200301773A patent/ES2235611B2/es not_active Expired - Fee Related
-
2004
- 2004-07-21 US US10/566,050 patent/US20110065138A1/en not_active Abandoned
- 2004-07-21 AT AT04742071T patent/ATE393833T1/de not_active IP Right Cessation
- 2004-07-21 ES ES07017630T patent/ES2368872T3/es not_active Expired - Lifetime
- 2004-07-21 AT AT07017630T patent/ATE514423T1/de not_active IP Right Cessation
- 2004-07-21 EP EP07017630A patent/EP1875906B1/en not_active Expired - Lifetime
- 2004-07-21 BR BRPI0412832-0A patent/BRPI0412832A/pt not_active Application Discontinuation
- 2004-07-21 WO PCT/ES2004/000343 patent/WO2005012543A2/es not_active Ceased
- 2004-07-21 JP JP2006520848A patent/JP2006528483A/ja active Pending
- 2004-07-21 CN CNA200480021338XA patent/CN1852988A/zh active Pending
- 2004-07-21 AU AU2004260895A patent/AU2004260895A1/en not_active Abandoned
- 2004-07-21 EP EP07017631A patent/EP1875907B1/en not_active Expired - Lifetime
- 2004-07-21 AT AT07017631T patent/ATE524174T1/de not_active IP Right Cessation
- 2004-07-21 DE DE602004013446T patent/DE602004013446D1/de not_active Expired - Lifetime
- 2004-07-21 CA CA002533600A patent/CA2533600A1/en not_active Abandoned
- 2004-07-21 EP EP04742071A patent/EP1647599B1/en not_active Expired - Lifetime
- 2004-07-21 RU RU2006101631/15A patent/RU2389488C2/ru not_active IP Right Cessation
- 2004-12-10 ES ES200402943A patent/ES2259266B2/es not_active Expired - Fee Related
- 2004-12-10 ES ES200402944A patent/ES2259894B2/es not_active Expired - Fee Related
-
2006
- 2006-03-27 JP JP2006084989A patent/JP2006325580A/ja active Pending
-
2010
- 2010-05-31 AU AU2010202237A patent/AU2010202237A1/en not_active Abandoned
- 2010-05-31 AU AU2010202232A patent/AU2010202232A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2259266A1 (es) | 2006-09-16 |
| ES2235611A1 (es) | 2005-07-01 |
| EP1875907B1 (en) | 2011-09-14 |
| ES2368872T3 (es) | 2011-11-23 |
| ES2259894B2 (es) | 2008-11-16 |
| RU2389488C2 (ru) | 2010-05-20 |
| ES2259266B2 (es) | 2008-06-01 |
| DE602004013446D1 (de) | 2008-06-12 |
| AU2010202232A1 (en) | 2010-07-08 |
| EP1875906A2 (en) | 2008-01-09 |
| EP1647599B1 (en) | 2008-04-30 |
| CA2533600A1 (en) | 2005-02-10 |
| EP1875907A2 (en) | 2008-01-09 |
| ATE393833T1 (de) | 2008-05-15 |
| EP1647599A2 (en) | 2006-04-19 |
| ES2235611B2 (es) | 2006-07-16 |
| EP1875906A3 (en) | 2008-02-27 |
| EP1875907A3 (en) | 2008-02-27 |
| RU2006101631A (ru) | 2006-08-27 |
| AU2004260895A1 (en) | 2005-02-10 |
| CN1852988A (zh) | 2006-10-25 |
| ES2259894A1 (es) | 2006-10-16 |
| WO2005012543A3 (es) | 2005-03-17 |
| EP1875906B1 (en) | 2011-06-29 |
| US20110065138A1 (en) | 2011-03-17 |
| ATE524174T1 (de) | 2011-09-15 |
| WO2005012543A2 (es) | 2005-02-10 |
| AU2010202237A1 (en) | 2010-06-24 |
| JP2006528483A (ja) | 2006-12-21 |
| ATE514423T1 (de) | 2011-07-15 |
| JP2006325580A (ja) | 2006-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR199901417T2 (xx) | Analjezik etkisi olan yeni bile�imler. | |
| Brocks et al. | Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer | |
| ATE323473T1 (de) | Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon | |
| BR9715022A (pt) | Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada | |
| DE60026538D1 (de) | Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen | |
| EP2210606A3 (en) | Compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases | |
| BRPI0415649A (pt) | método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica | |
| DE69826644D1 (de) | Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker | |
| ES2164040T1 (es) | Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos. | |
| MX9200992A (es) | Composicion farmaceutica que tiene como ingrediente activo 3-[2-(dimetilamino)etil]-n-metil-1h-indol-5-metanosulfonamida y procedimiento para su preparacion. | |
| BRPI0309544B8 (pt) | preparação farmacêutica oral estável ao armazenamento compreendendo oxicodona e naloxona | |
| DE602004032149D1 (de) | Oros-push-stick für die kontrollierte abgabe von wirkstoffen | |
| EA200800161A1 (ru) | Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций | |
| BRPI0413974A (pt) | combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação | |
| WO2004039325A3 (en) | Treatment of pain with jnk inhibitors | |
| CA2387486A1 (en) | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders | |
| BRPI0406796A (pt) | Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina | |
| BRPI0406858A (pt) | Liberação controlada de agentes altamente solúveis | |
| NO994165L (no) | Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet | |
| BRPI0412832A (pt) | uso terapêutico das yessotoxinas como inibidores do crescimento de células tumorais humanas | |
| TW200420290A (en) | Methods for the treatment, prevention and management of macular degeneration | |
| BRPI0413474A (pt) | uso de interferon e ribavirina e kit para uso no tratamento de infecções virais | |
| AR048806A1 (es) | Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio | |
| DE60301862D1 (de) | Kombinationsbehandlung bei akutem myokardinfarkt | |
| BRPI0415651A (pt) | métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |